Idorsia Pharmaceuticals Ltd (IDRSF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the iDOSIA Half Year 2025 Financial Results webcast and conference call. At this time all participants are in listen only mode. After the speaker's presentation, there will be the question and answer session. To ask a question during a session, you need to press star one one on your telephone keypad. You will hear an automatic message advising your hand is raised. To withdraw a question, please press star one one again. Please be advised that this conference is being recorded. I would not like to hand the conference over to our first speaker today, Andrew Jones, head of corporate communications. Please go ahead. Thank you Nadia. Good afternoon and good morning everyone and welcome to our webcast to discuss the financial results for the first half of 2025. Presented on the call today, we have our new CEO Srishti Gupta, who will share her impressions of her first weeks in the new position and the company's revised strategic priorities. Also presenting, we have Arnold Grunewald, our chief financial officer. Then joining us for the Q&A session, we have a big selection of management. We've got Julian Gander in his new role of chief legal and corporate development officer. Our president of the UCAN region, Benjamin Limahl. Our president of the US, Michael Moy and chief scientific officer and newly appointed head of research, Martin Kozell. And Alberto Gimona, our global head of clinical development and medical affairs. Next slide. Before handing over, I need to remind everyone that we will be making forward looking statements. You have therefore been warned appropriately about the risks and opportunities of investing in iDorSia. And with that, I will hand over to our new CEO, Srishti Gupta. Next slide. Good morning, good afternoon everyone. Thank you for joining...